BioAlign is developing Growth driven technology to treat Scoliosis
3 million children are diagnosed with Scoliosis and 40,000 scoliosis correction surgeries are performed in the United States every year.
Current Standard of Care has a complications rate of 30-50%.
BioAlign Mission is to change the Standard of Care for treating children suffering from Scoliosis. Our Vision is to become the pre-eminent Pediatric Scoliosis Patient Specific Growth Driven Implants Company in the world.
Patient Specific Growth Driven
Patient Specific Distraction Procedure
Self-Actuating Growth Rods
Patient Specific Growth Data Monitoring
Our Team.
After decades long successful careers in large corporations, developing and commercializing innovative spinal implants which have today shaped the spinal implants industry, the BioAlign team ventured out to solve the biggest unsolved problem in spine surgery: A 30-50% complications rate in todays' EOS Standard of Care.
Armed with a cumulative experience of 100+ years in Spine Product Development, US FDA Approvals & Commercialization, and a bullish attitude towards Disruptive Innovation, the BioAlign Team has developed a 1st of its kind technology to solve this problem so that no parent has to hear that: "There is a 30-50% chance that your child may undergo a revision surgery".
We Take Pride in Our Numbers
100+
Years of Experience
7
Countries Patented In World Wide
16+
Granted Patents
